Repare reports Q2 net loss $0.39/share; enters lunresertib licensing deal, evaluating strategic alt

Repare Therapeutics Inc.

2025-Q2 EPS reported -$1.09

Q2 net loss $16.7M ($0.39/share); revenue from collaboration $0.3M vs $1.1M prior year.
Licensed lunresertib to Debiopharm; $10M upfront, up to $257M milestones plus single-digit royalties.
Out-licensed discovery platforms to DCx; $1M upfront, $3M near-term, 9.99% equity stake.
Cash $109.5M at June 30, 2025; initial LIONS and POLAR trial data expected Q4 2025.
Company evaluating strategic alternatives including partnerships and sale opportunities for portfolio.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.